| 0.6601 -0.144 (-17.95%) | 11-20 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Acer Therapeutics Inc. is a pharmaceutical company dedicated to acquiring, developing, and commercializing treatments for severe rare and life-threatening conditions. Its clinical-stage pipeline features four key candidates: EDSIVO, for vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a sodium phenylbutyrate formulation addressing inborn errors of metabolism such as urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant), designed to manage induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy showing promise against various infectious diseases, including COVID-19. The company also collaborates with the National Center for Advancing Translational Sciences (NCATS) on developing emetine hydrochloride for COVID-19 and holds worldwide licensing rights for osanetant, a selective NK3 receptor antagonist, through an agreement with Sanofi. Established in 1991, Acer Therapeutics Inc. is headquartered in Newton, Massachusetts.
Wed, 13 Aug 2025
Zevra Therapeutics Crashes, Reversing 89% Run. Why It Could Be An 'Overreaction.' - Investor's Business Daily
Mon, 20 Nov 2023
Zevra Therapeutics Acquires Acer Therapeutics - Contract Pharma
Fri, 15 Sep 2023
Zevra adds Edsivo for vEDS to its rare disease portfolio in new deal - Ehlers-Danlos News
Thu, 31 Aug 2023
Acer stabilizes with Zevra merger and Relief deal - BioWorld News
Thu, 31 Aug 2023
Zevra strikes $91M buyout of Acer to catapult itself into commercial rare disease space - Fierce Pharma
Thu, 31 Aug 2023
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|